Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kadmon Holdings, Inc.

http://kadmon.com

Latest From Kadmon Holdings, Inc.

Patient-Reported Outcomes: Open-Label Trials Can Be Designed To Minimize Bias, US FDA Says

With the expectation for increasing amounts of patient experience data comes the need for the FDA and sponsors to consider, and account for, the degree to which open-label bias influences oncology trial PROs; agency staff suggest trial design elements and analytic approaches for dealing with bias at a meeting on cancer clinical outcomes assessments.

Drug Review Clinical Trials

Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains

While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.

Market Snapshot Rare Diseases

Finance Watch: Q1 Biopharma IPOs Shrink To A Fraction Of 2021 Total

Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.

Financing Innovation

Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Growth Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Kadmon Corporation, LLC
    • Phytoceutical
    • Romeck Pharma, LLC
    • Sanofi
    • Three Rivers Pharmaceuticals, LLC
UsernamePublicRestriction

Register